Related Experiment Videos
Nonantimicrobial aspects of therapy
1National Heart and Lung Institute, Imperial College, London, UK.
Seminars in Respiratory Infections
|April 5, 2000
Summary
Current chronic obstructive pulmonary disease (COPD) treatments manage symptoms but do not halt disease progression. Lifestyle changes like smoking cessation and pulmonary rehabilitation are key, with new drug therapies under development.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Current therapies for chronic obstructive pulmonary disease (COPD) are primarily symptomatic.
- No available treatments effectively prevent COPD disease progression.
Purpose of the Study:
- To review current therapeutic strategies for COPD.
- To discuss the limitations of existing treatments and explore emerging drug classes.
Main Methods:
- Literature review of current COPD management.
- Analysis of the efficacy and limitations of pharmacological and non-pharmacological interventions.
- Overview of novel therapeutic agents in development.
Main Results:
- Smoking cessation, facilitated by nicotine replacement or bupropion, is the only proven method to impact COPD progression.
- Inhaled beta2-agonists and anticholinergics are mainstays of symptomatic treatment.
- Inhaled corticosteroids offer minimal benefit for disease progression and carry potential systemic risks.
- Pulmonary rehabilitation, exercise, nutrition, and surgery are valuable non-pharmacological measures.
- New drug classes, including phosphodiesterase-4 inhibitors, show promise.
Conclusions:
- There is a critical need for therapies that address the underlying pathology of COPD.
- Further research into disease mechanisms is essential for developing more effective treatments.